文献速递心脑血管急症重症综合管理与镇静镇痛

高渗乳酸改善急性脑损伤后脑灌注与葡萄糖可用性

Hypertonic Lactate to Improve Cerebral Perfusion and Glucose Availability After Acute Brain Injury.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论高渗乳酸输注可增加脑损伤患者脑血流速度和脑微透析葡萄糖,且不依赖全身血流动力学改变。

该前瞻性研究纳入23例脑损伤患者(13例创伤性脑损伤/10例蛛网膜下腔出血),在伤后39小时(26-49小时)静脉输注高渗乳酸(乳酸钠,1000 mmol/L;浓度30 µmol/kg/min)3小时。结果显示脑微透析乳酸增加55%(31-80%),大脑中动脉平均脑血流速度增加36%(21-66%),搏动指数降低21%(13-26%),脑微透析葡萄糖增加42%(30-78%),均具统计学意义。脑灌注压、平均动脉压、全身二氧化碳和血糖无显著变化。结论认为高渗乳酸复苏改善脑灌注和脑葡萄糖可用性,其效应与脑乳酸补充相关而非全身效应。

要点

  • 23例脑损伤患者(13例创伤性脑损伤/10例蛛网膜下腔出血)在伤后39小时(26-49小时)接受3小时静脉输注高渗乳酸(乳酸钠,1000 mmol/L;浓度30 µmol/kg/min)。
  • 高渗乳酸输注使脑微透析乳酸增加55%(31-80%),大脑中动脉平均脑血流速度增加36%(21-66%),搏动指数降低21%(13-26%),均p<0.001。
  • 脑微透析葡萄糖增加42%(30-78%)(p<0.05),且基线脑葡萄糖可用性降低与脑微透析葡萄糖改善程度相关(Spearman r=-0.53;p=0.009)。
  • 57%(13/23)的患者在基线时脑微透析葡萄糖<1 mmol/L,尽管基线颅内压正常(10 [7-15] mm Hg)。
  • 输注期间脑灌注压、平均动脉压、全身二氧化碳和血糖无显著变化(均p>0.1)。

适用人群与场景

  • 23例脑损伤患者(13例创伤性脑损伤/10例蛛网膜下腔出血),中位年龄59岁(41-65岁),中位格拉斯哥昏迷评分6分(3-7分)。
  • 学术型ICU内,伤后39小时(26-49小时)接受干预。

诊断标准与关键阈值

  • 基线脑微透析葡萄糖<1 mmol/L定义为脑葡萄糖可用性降低。
  • 基线颅内压正常定义为10(7-15)mm Hg。

处置流程与药物剂量

  • 静脉输注高渗乳酸(乳酸钠,1000 mmol/L;浓度30 µmol/kg/min)持续3小时,于伤后39小时(26-49小时)给药。

研究设计与关键结果

  • 前瞻性研究(clinicaltrials.gov NCT01573507),纳入23例脑损伤患者,在学术型ICU进行。
  • 干预为3小时静脉输注高渗乳酸(乳酸钠,1000 mmol/L;浓度30 µmol/kg/min),于伤后39小时(26-49小时)给药。
  • 脑微透析乳酸增加55%(31-80%),大脑中动脉平均脑血流速度增加36%(21-66%),搏动指数降低21%(13-26%),均p<0.001。
  • 脑微透析葡萄糖增加42%(30-78%)(p<0.05);基线脑葡萄糖可用性降低与脑微透析葡萄糖改善程度相关(Spearman r=-0.53;p=0.009)。
  • 脑灌注压、平均动脉压、全身二氧化碳和血糖无显著变化(均p>0.1)。

证据类型、等级与局限

  • 前瞻性研究(clinicaltrials.gov NCT01573507)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为高渗乳酸复苏改善脑损伤后脑灌注和脑葡萄糖可用性,这些脑血管和代谢效应似乎与脑乳酸补充相关而非全身效应。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Lactate promotes cerebral blood flow and is an efficient substrate for the brain, particularly at times of glucose shortage. Hypertonic lactate is neuroprotective after experimental brain injury; however, human data are limited.

DESIGN: Prospective study (clinicaltrials.gov NCT01573507).

SETTING: Academic ICU.

PATIENTS: Twenty-three brain-injured subjects (13 traumatic brain injury/10 subarachnoid hemorrhage; median age, 59 yr [41-65 yr]; median Glasgow Coma Scale, 6 [3-7]).

INTERVENTIONS: Three-hour IV infusion of hypertonic lactate (sodium lactate, 1,000 mmol/L; concentration, 30 µmol/kg/min) administered 39 hours (26-49 hr) from injury.

MEASUREMENTS AND MAIN RESULTS: We examined the effect of hypertonic lactate on cerebral perfusion (using transcranial Doppler) and brain energy metabolism (using cerebral microdialysis). The majority of subjects (13/23 = 57%) had reduced brain glucose availability (baseline pretreatment cerebral microdialysis glucose, < 1 mmol/L) despite normal baseline intracranial pressure (10 [7-15] mm Hg). Hypertonic lactate was associated with increased cerebral microdialysis lactate (+55% [31-80%]) that was paralleled by an increase in middle cerebral artery mean cerebral blood flow velocities (+36% [21-66%]) and a decrease in pulsatility index (-21% [13-26%]; all p < 0.001). Cerebral microdialysis glucose increased above normal range during hypertonic lactate (+42% [30-78%]; p < 0.05); reduced brain glucose availability correlated with a greater improvement of cerebral microdialysis glucose (Spearman r = -0.53; p = 0.009). No significant changes in cerebral perfusion pressure, mean arterial pressure, systemic carbon dioxide, and blood glucose were observed during hypertonic lactate (all p > 0.1).

CONCLUSIONS: This is the first clinical demonstration that hypertonic lactate resuscitation improves both cerebral perfusion and brain glucose availability after brain injury. These cerebral vascular and metabolic effects appeared related to brain lactate supplementation rather than to systemic effects.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Carteron L, Solari D, Patet C, et al. Hypertonic Lactate to Improve Cerebral Perfusion and Glucose Availability After Acute Brain Injury. Crit Care Med. 2018. PMID: 29923931. doi:10.1097/CCM.0000000000003274

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。